Gesynta Pharma

Executive Summary

Gesynta Pharma is a Swedish private biotechnology company focused on developing novel small-molecule drugs that target microvascular inflammation and blood flow. Their lead candidate, GS-248, has completed a Phase 2 trial in systemic sclerosis (NCT04744207) and a Phase 1 pharmacokinetic study. The most advanced active program is vipoglanstat, a Phase 2 drug for endometriosis (NCT07260669), which is currently recruiting and expected to complete in mid-2027. The company's platform addresses diseases with high unmet medical need by modulating microvasculature dysfunction, offering potential for safer and more effective treatments. With a strong scientific foundation and two completed Phase 1/2 trials, Gesynta is positioned for significant value inflection pending clinical data and strategic partnerships.

Upcoming Catalysts (preview)

• H2 2026Vipoglanstat Phase 2 Endometriosis Interim Data60% success
• Q1 2027GS-248 Phase 3 Initiation in Systemic Sclerosis45% success
• 2026Series B Financing or Licensing Deal70% success